Optimized multiparametric flow cytometric analysis of circulating endothelial cells and their subpopulations in peripheral blood of patients with solid tumors: a technical analysis

Abstract

BackgroundCirculating endothelial cells (CECs) and their subpopulations could be potential novel biomarkers for various malignancies. However, reliable enumerable methods are warranted to further improve their clinical utility. This study aimed to optimize a flow cytometric method (FCM) assay for CECs and subpopulations in peripheral blood for patients with solid cancers.Patients and methodsAn FCM assay was used to detect and identify CECs. A panel of 60 blood samples, including 44 metastatic cancer patients and 16 healthy controls, were used in this study. Some key issues of CEC enumeration, including sample material and anticoagulant selection, optimal titration of antibodies, lysis/wash procedures of blood sample preparation, conditions of sample storage, sufficient cell events to enhance the signal, fluorescence-minus-one controls instead of isotype controls to reduce background noise, optimal selection of cell surface markers, and evaluating the reproducibility of our method, were integrated and investigated. Wilcoxon and Mann–Whitney U tests were used to determine statistically significant differences.ResultsIn this validation study, we refined a five-color FCM method to detect CECs and their subpopulations in peripheral blood of patients with solid tumors. Several key technical issues regarding preanalytical elements, FCM data acquisition, and analysis were addressed. Furthermore, we clinically validated the utility of our method. The baseline levels of mature CECs, endothelial progenitor cells, and activated CECs were higher in cancer patients than healthy subjects (P<0.01). However, there was no significant difference in resting CEC levels between healthy subjects and cancer patients (P=0.193).ConclusionWe integrated and comprehensively addressed significant technical issues found in previously published assays and validated the reproducibility and sensitivity of our proposed method. Future work is required to explore the potential of our optimized method in clinical oncologic applications.

Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers

“…Endothelial cells can enter circulation as CECs when sloughing off vessel walls and as endothelial progenitor cells (EPCs) when mobilized from the bone marrow. 36 Both CECs and their populations, which can be enumerated by flow cytomery, 56 – 58 could potentially serve as biomarkers for the prognosis and prediction of various solid tumors. 36 CECs and EPCs appear to change dynamically during the course of chemotherapy of patients with breast cancer.…”

The impact of different forms of exercise on circulating endothelial progenitor cells in cardiovascular and metabolic disease

“…Van Craenenbroeck et al ( 2008 ) found moderate to poor agreement between six different flow cytometric gating strategies for EPC quantification. Finally, flow cytometry related analytical factors possibly can explain part of the variability on findings within the same clinical population since the volume of blood samples, storage protocol, anti-coagulant tube selection, a wash step or not for red blood cell lysis and units of EPC expression are essential for reliable and accurate EPC enumeration (Hoymans et al 2012 ; Van Craenenbroeck et al 2013 ; Zhou et al 2018 ).…”